Cancer Research Horizons
Cancer Research Horizons is a London-based organization dedicated to the development and commercialization of innovations in cancer research. Established in 1982, it serves as a critical connection between academia and industry, leveraging its deep understanding of both sectors to transform promising research into viable commercial solutions that benefit patients while maximizing financial returns. The organization is uniquely positioned to draw on the extensive research and partnerships fostered by its parent entity, Cancer Research UK, the leading charitable funder of cancer research globally. With over 30 years of specialized experience, Cancer Research Horizons has a proven track record in advancing cancer therapeutics, diagnostics, and related technologies. Its team, comprised of experienced and motivated professionals, is divided between drug discovery and commercialization, ensuring a comprehensive approach to delivering breakthrough therapies to patients.
52 North Health aims to improve healthcare with a medical device that uses artificial intelligence (AI) to determine the risk of neutropenic sepsis for patients undergoing chemotherapy.
Infinitopes is a cancer research organization focused on enhancing the immune system to prevent metastases and ultimately save lives. The company develops healthcare systems and therapeutic designs that integrate advanced tumor target identification technologies with efficient vector delivery systems. By applying this innovative platform in early-stage clinical trials, Infinitopes aims to improve patient outcomes in the fight against cancer and tumors, offering new hope for those affected by these diseases.
Neobe Therapeutics provides immunotherapies, clinical trials, research, and tumor-colonizing bacteria engineering services.
Trogenix operates as a therapeutics company, that treats aggressive cancers.
NK:IO is a biotechnology company focused on advancing natural killer cell-mediated immunotherapy, particularly in the realm of cancer treatment. The company specializes in developing innovative cell therapies and small molecule therapeutics designed to enhance the effectiveness of cancer targeting for physicians. By leveraging cutting-edge research and technology, NK:IO aims to improve treatment outcomes for patients facing cancer.
Elaitra specializes in advanced breast cancer detection through its innovative digital breast tomosynthesis imaging technology. The company has developed a generative language model for voice-based patient engagement, alongside a unique AI tool that assists healthcare professionals in interpreting 3D X-rays. Elaitra's solutions enhance early detection and diagnosis by providing a viewing assistant and computer-assisted diagnosis for effective triage. With regulatory approvals from the FDA and UK authorities, Elaitra operates in both the United States and the United Kingdom, aiming to improve patient outcomes in breast cancer treatment.
BioCaptiva is a developer of innovative liquid biopsy technology that focuses on the early diagnosis and monitoring of difficult-to-detect cancers. The company's platform is designed to capture circulating free DNA from patients' blood in larger quantities, addressing the limitations commonly associated with current liquid biopsy testing methods. This advancement enables healthcare professionals to explore new approaches for detecting and monitoring various cancers, ultimately aiming to improve patient outcomes through more effective diagnostics.
Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer. The company's immunotherapies harness the immune system to destroy cancer cells that target truncal tumor neo-antigens and flags to the immune system present on the surface of every cancer cell, enabling scientists to target and destroy tumors without harming healthy tissues.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.